Ubs Asset Management Americas Inc Nektar Therapeutics Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.64 - $3.15 $26,549 - $130,671	41,483 Added 24.81%	208,662 $146,000
Q3 2022 Nov 14, 2022	SELL	$3.04 - $5.14 $84,277 - $142,496	-27,723 Reduced 14.22%	167,179 $534,000
Q2 2022 Aug 12, 2022	SELL	$3.17 - $6.17 $345,758 - $672,974	-109,072 Reduced 35.88%	194,902 $740,000
Q1 2022 May 16, 2022	BUY	$4.16 - $13.72 $176,454 - $581,961	42,417 Added 16.22%	303,974 $1.64 Million
Q4 2021 Feb 14, 2022	BUY	$10.83 - $18.41 $18,865 - $32,070	1,742 Added 0.67%	261,557 $3.53 Million
Q2 2021 Aug 16, 2021	BUY	$16.52 - $20.4 $119,423 - $147,471	7,229 Added 2.86%	259,815 $4.46 Million
Q1 2021 May 14, 2021	SELL	$16.56 - $25.46 $24,955 - $38,368	-1,507 Reduced 0.59%	252,586 $5.05 Million
Q4 2020 Mar 01, 2021	BUY	$15.77 - $19.03 $555,561 - $670,407	35,229 Added 16.1%	254,093 $4.32 Million
Q3 2020 Nov 13, 2020	BUY	$16.59 - $24.79 $78,089 - $116,686	4,707 Added 2.2%	218,864 $3.63 Million
Q2 2020 Aug 14, 2020	SELL	$16.86 - $23.44 $544,021 - $756,338	-32,267 Reduced 13.09%	214,157 $4.96 Million
Q1 2020 May 15, 2020	BUY	$14.47 - $27.96 $264,699 - $511,472	18,293 Added 8.02%	246,424 $4.4 Million
Q4 2019 Feb 14, 2020	SELL	$15.87 - $23.12 $3.84 Million - $5.6 Million	-242,124 Reduced 51.49%	228,131 $4.93 Million
Q3 2019 Nov 14, 2019	SELL	$16.91 - $36.27 $3.37 Million - $7.23 Million	-199,299 Reduced 29.77%	470,255 $8.57 Million
Q2 2019 Aug 15, 2019	SELL	$31.0 - $36.3 $2.13 Million - $2.49 Million	-68,684 Reduced 9.3%	669,554 $0
Q1 2019 May 14, 2019	BUY	$31.58 - $46.35 $189,858 - $278,656	6,012 Added 0.82%	738,238 $0
Q4 2018 Feb 13, 2019	BUY	$30.43 - $56.65 $2.53 Million - $4.71 Million	83,138 Added 12.81%	732,226 $24.1 Million
Q3 2018 Nov 14, 2018	BUY	$46.46 - $68.49 $2.82 Million - $4.16 Million	60,685 Added 10.31%	649,088 $0
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $16.7 Million - $37.6 Million	360,071 Added 157.7%	588,403 $0
Q1 2018 May 14, 2018	BUY	$57.4 - $108.44 $426,941 - $806,576	7,438 Added 3.37%	228,332 $0
Q4 2017 Feb 09, 2018	SELL	$23.02 - $60.5 $4.42 Million - $11.6 Million	-192,052 Reduced 46.51%	220,894 $0
Q3 2017 Nov 13, 2017	BUY	$17.79 - $24.0 $7.35 Million - $9.91 Million	412,946	412,946 $0

Others Institutions Holding NKTR

# of Institutions

145

Shares Held

139M

Call Options Held

32.6K

Put Options Held

14.1K

Deep Track Capital, LP Greenwich, CT

15.9M
Shares

$14.8 Million
0.76% of portfolio
Black Rock Inc. New York, NY

15.2M
Shares

$14.1 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

13.1M
Shares

$12.2 Million
0.0% of portfolio
Eventide Asset Management, LLC Boston, MA

9.4M
Shares

$8.74 Million
0.22% of portfolio
Samlyn Capital, LLC New York, NY

9.2M
Shares

$8.56 Million
0.19% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account